ummary: A study has been performed on the effect of, J Noriyl-1 and Ortho-Novin, two low-dose oral contraceptives, on blood-clotting factors. Ortho-Novin contains twice the amount of hormone as Norinyl-1. It was therefore possible to observe whether any changes detected were related to the dose of oestrogen-progestin combination. The women were tested in parallel with matched normal female controls and a group in the third trimester of pregnancy. Significant rises in factor VII and X levels were found with both low-dose preparations from the third month onwards. There was no difference between patients on Norinyl-I and Ort&-Novin, and hence the clotting changes do not appear to be dose-dependent. The long-term effects on clotting factors of these lowdose oral contraceptive preparations remain to be investigated.
Introduction
In previous studies we found an increase in plasma clotting factors VII and X in women taking oral contraceptive preparations, and this rise became statistically significant from the third month onwards (Thomson and Poller, 1965; Poller and Thomson, 1966) . The present investigations were designed to determine whether this effect depended on the dose of antiovulatory agent, and whether the time relationship of the consequent changes would be affected by the hormonal dose. Women volunteers were given two different preparations of relatively low hormonal content, one of which-Ortho-Novincontained twice the dose (norethisterone 2 mg., mestranol 0.1 mg.) of the other-Norinyl-l. Parallel studies were performed on women controls and a group of patients in their third trimester of pregnancy.
Method of Study
The %women of this investigation volunteered to co-operate in the study following an appeal for participants in a trial of low-dose oral contraceptives. Their clotting factors were studied before starting the "pill" preparations. They were tested at intervals of six weeks for three months, and then at intervals of three months for nine months. This report deals with the results to the nine-month stage.
The women participating consisted of 31 patients on OrthoNovin who had not previously taken oral contraceptives and 60 women on Norinyl-1. Of the latter group 34 had not previously taken oral contraceptives and 26 had been taking some other preparation within the preceding six months. An antenatal group consisting of 43 ambulatory patients in the third trimester of pregnancy attending Withington Maternity Hospital were studied as a control group. The normal group consisted of equal numbers of matched normal females tested at the same time as the oral contraceptive and antenatal patients.
To eliminate possible variables that occur in assays owing to alteration in reagents and other factors from day to day, each of the oral contraceptive groups was compared statistically with the simultaneous parallel group of normals and the antenatal patients.
Technique.-The method for prothrombin activity (Quick's test), cephalin time, and factor VII and factor X assays were as described previously. The method for the kaolin-activated cephalin time was the cephalin time method as described by Hjort et al. (1955) , modified by the addition of kaolin.
Results
Of the original 91 patients 75 were still in the trial after their sixth monthly course and 56 patients were left after the ninth course. Of the three oral contraceptive groups 18 remained on Ortho-Novin and 21 and 17 respectively in the two Norinyl-1 groups after nine months.
When the results of the patients taking oral contraceptives were compared as groups with their parallel normal controls as well as with the parallel antenatal groups there was no significant difference in the prothrombin time results between any of the groups. Analysis of the cephalin times showed a significant shortening (P=0.05) with the unmodified test and with the kaolin-activated test from the sixth month onwards, but only when all the oral contraceptive patiht we considered as a combined group.
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The factors VII and X levels were significantly increased in the combined group and in each of the three individual groups of patients on oral contraceptives from the third month onwards. There was no significant difference between the patients on Norinyl-1 and Ortho-Novin when these were compared. The second group of Norinyl-l patients-that is, those who had been on other preparations of oral contraceptives previously-showed a significantly raised level of factor X before starting Norinyl-l, which persisted and continued to rise progressively during the study. The Table gives 
Comment
This study on low-dose oral contraceptives confirms our previous reports that increases of factor VII and factor X result and reach a significant level after the third month. Both Norinyl-1 and Ortho-Novin contain smaller doses of hormones than the older proprietary preparations we studied previously. It was possible, therefore, that clotting-factor increases might not result or might be delayed with the reduced dosage. In this study we used one progestin-oestrogen combination exactly twice the hormonal content of the other preparation to see if a difference in degree of timing or clotting-factor increase resulted. In actual practice the coagulation response appeared to be identical. In other words, the changes do not appear to be a simple matter of dose-dependency.
Previously we have shown that after two years the rise in factor VII levels was of the same order of increase as occurs in the third trimester of pregnancy. In the present investigation women on oral contraceptives at nine months still showed less clotting-factor changes than women at the same period of normal pregnancy. Further studies must be carried out to see whether factor VII levels increase to the same extent as with the older, larger dose preparations after two years. It must be emphasized that the changes we have shown are only part of the spectrum of clotting-factor increases which occur during normal pregnancy, when the thrombosis risk, though increased, is still small, and the factor VII changes we showed previously in patients on oral contraceptives were not as marked as those present in venous thrombosis (Thomson and Poller, 1965 The lack of different factor VII levels between the two groups on Norinyl-1 is probably explained by the fact that in the group who had already taken oral contraceptives most of the patients had had a break of at least one month between taking their previous preparations and starting their course. These results partly confirm the view reported by Schrogie et al. (1967) that the effect oi the oestrogen-progestin combination disappears within one month of stopping.
In contrast a persistent rise in factor X after stopping one preparation and changing to Norinyl-l is noteworthy. The disappointing feature is the progressive rise in factor X that occurred on changing to Norinyl-1 and its persistence throughout our study. It is obvious that further work is required to determine whether the effects on clotting factors induced by oral contraceptive agents can be minimized by other approaches than simple reduction of dosage in a conventional combined preparation.
